Literature DB >> 1941627

Comparative pharmacology of the nitrobenzylthioguanosine-sensitive and -resistant nucleoside transport mechanisms of Ehrlich ascites tumor cells.

J R Hammond1.   

Abstract

A variety of nucleoside transport inhibitors and substrates were compared for their capacities to inhibit the zero-trans influx of [3H]uridine in Ehrlich ascites tumor cells. ATP-depleted cells accumulated [3H]uridine primarily by facilitated diffusion (Vmax = 16 pmol/sec/microliter cell water) via both nitrobenzylthioguanosine (NBTGR)-sensitive (IC50 = 0.53 nM, 100 microM [3H]uridine) and NBTGR-resistant (IC50 = 71 microM, 100 microM [3H]uridine) mechanisms with uridine Km estimates of 99 and 284 microM, respectively. Dilazep also distinguished between the transporter subtypes with IC50 values of 1.4 nM and 1.8 microM, respectively, for inhibiting 100 microM [3H]uridine influx. Incubation of cells with 50 nM NBTGR allowed the selective study of inhibitor effects on NBTGR-resistant [3H]uridine influx. Dipyridamole, cyclopentyladenosine, 2-phenylaminoadenosine, etoposide, teniposide, diazepam, chlordiazepoxide, triazolam and the lidoflazine derivative 2-(aminocarbonyl)-N-(4-amino-2,6-dichlorophenyl)-4-[5,5-bis-(4- fluorophenyl)pentyl]-1-piperazineacetamide (R75231), were significantly less potent as inhibitors of NBTGR-resistant influx, when compared with their capacities to inhibit the total mediated influx of [3H]uridine. In contrast, 2-fluoroadenosine, 2-chloroadenosine, 5'-N-ethylcarboxamidoadenosine and soluflazine were relatively more effective as inhibitors of the NBTGR-resistant component. Mioflazine, a compound related to both soluflazine and R75231, did not distinguish between transporter subtypes. The NBTGR-resistant transporter also had a distinctive substrate specificity; guanosine, 2'-deoxyguanosine, cytidine and 2'-deoxycytidine were significantly less effective as inhibitors of NBTGR-resistant [3H]uridine influx.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1941627

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells.

Authors:  David A Plotnik; Lindsay E Emerick; Kenneth A Krohn; Jashvant D Unadkat; Jeffrey L Schwartz
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

Review 2.  Equilibrative nucleoside transporters-A review.

Authors:  Rebba C Boswell-Casteel; Franklin A Hays
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2016-10-19       Impact factor: 1.381

3.  Subtype-specific regulation of equilibrative nucleoside transporters by protein kinase CK2.

Authors:  Meaghan Stolk; Elizabeth Cooper; Greg Vilk; David W Litchfield; James R Hammond
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

4.  Molecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain.

Authors:  A Kiss; K Farah; J Kim; R J Garriock; T A Drysdale; J R Hammond
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

5.  Coordination of ENT2-dependent adenosine transport and signaling dampens mucosal inflammation.

Authors:  Carol M Aherne; Colm B Collins; Caroline R Rapp; Kristine E Olli; Loni Perrenoud; Paul Jedlicka; Jessica L Bowser; Tingting W Mills; Harry Karmouty-Quintana; Michael R Blackburn; Holger K Eltzschig
Journal:  JCI Insight       Date:  2018-10-18

6.  Differential uptake of [3H]guanosine by nucleoside transporter subtypes in Ehrlich ascites tumour cells.

Authors:  J R Hammond
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

7.  Decrease in equilibrative uridine transport during monocytic differentiation of HL-60 leukaemia: involvement of protein kinase C.

Authors:  C W Lee
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

8.  Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.

Authors:  N J Curtin; K J Bowman; R N Turner; B Huang; P J Loughlin; A H Calvert; B T Golding; R J Griffin; D R Newell
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

9.  Expression and purification of human and Saccharomyces cerevisiae equilibrative nucleoside transporters.

Authors:  Rebba C Boswell-Casteel; Jennifer M Johnson; Zygy Roe-Žurž; Kelli D Duggan; Hannah Schmitz; Franklin A Hays
Journal:  Protein Expr Purif       Date:  2017-09-14       Impact factor: 1.650

10.  Clearance of rapid adenosine release is regulated by nucleoside transporters and metabolism.

Authors:  Michael D Nguyen; Ashley E Ross; Matthew Ryals; Scott T Lee; B Jill Venton
Journal:  Pharmacol Res Perspect       Date:  2015-11-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.